The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma

Chest

Volumn 119, Issue 5, 2001, Pages 1533-1546

  Salvi, S S ^a   Krishna, M T ^a   Sampson, A P ^a   Holgate, S T ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Anti inflammatory; Antileukotrienes; Aspirin induced asthma; Asthma; Corticosteroids; Eosinophil; Inflammation

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; AUTACOID; BECLOMETASONE DIPROPIONATE; CINALUKAST; CORTICOSTEROID; GLUCOCORTICOID; HISTAMINE; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONOCLONAL ANTIBODY; MONTELUKAST; PEPTIDOLEUKOTRIENE; PRANLUKAST; SALMETEROL; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CELL ACTIVITY; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDEMA; EOSINOPHIL; HUMAN; MUCUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER;

EID: 0034929204     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.5.1533     Document Type: Article

References (137)

1. The cellular and mediator basis of asthma in relation to natural history
2. Methods for bronchoalveolar lavage in asthmatic patients after broncho-provocation and local antigen challenge
3. Eosinophilic inflammation in asthma
4. Lymphokines in asthma
5. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production
6. Cytokines: 3. Cytokines in asthma
7. Are you TH-1 or TH-2?
8. The one-two of T helper cells: Does interferon-γ knock out the Th2 hypothesis for asthma?
9. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation
10. Role of epithelial cells in asthma
11. Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells: Modulation by corticosteroids and T-helper 2 cytokines
12. Constitutive and cytokine-stimulated expression of eotaxin by human airway smooth muscle cells
13. Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts
14. Leukotrienes and airway responses
15. 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes
16. The expression of leukotriene pathway enzymes in human bronchial epithelial cells
17. 15-Lipoxygenase immunoreactivity in normal and in asthmatic airways
18. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis
19. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor
20. 1 receptor
21. Lack of increased numbers of low-density eosinophils in the circulation of asthmatic individuals
22. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor
23. Expression of 5-lipoxygenase and 5-lipoxygenase-activating protein mRNAs in the peripheral blood leukocytes of asthmatics
24. Interleukin-5 production by human airway epithelial cells
25. IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils
26. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients
27. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge
28. Bronchoalveolar lavage fluid mediator levels 5 min after allergen challenge in atopic subjects with asthma: Relationship to the development of late asthmatic responses
29. Measurements of leukotrienes in the urine: Strategies and applications
30. 4 after antigen challenge and in acute asthma and allergic rhinitis
31. 4 levels after allergen and exercise challenge in bronchial asthma
32. 4, and histamine in asthmatics
33. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects
34. 4 excretion in aspirin-sensitive asthma
35. Treatment of asthma with drugs modifying the leukotriene pathway
36. Role of leukotrienes in airway hyperresponsiveness in guinea-pigs
37. Airway hyperresponsiveness to acetylcholine induced by aerosolized arachidonic acid metabolites in guinea-pigs
38. 4 in guinea-pigs
39. 4 enhance histamine responsiveness in asthmatic airways
40. Cysteinyl-leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice
41. Pharmacology of leukotriene receptor antagonists: More than inhibitors of bronchoconstriction
42. 4 in allergen-induced increases in airway smooth muscle in the rat
43. 4 increase the release of mucus from human airways in vitro
44. Mucociliary clearance in the airways
45. 4 on ciliary activity in human, guinea-pig and rat respiratory mucosa
46. 4 increase the ciliary beat frequency in human upper airway mucosa in vitro
47. Abnormal mucociliary transport in allergic patients with antigen-induced bronchospasm: Role of slow reacting substance of anaphylaxis
48. 4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody
49. Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats
50. 4 and granulocytic infiltration into asthmatic airways
51. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro
52. Induced sputum, nitric oxide and lung function response to leukotriene D4 bronchoprovocation in asthma
53. 4 on canine bronchial smooth muscle
54. Role of peptidoleukotrienes in capsaicin-sensitive sensory fiber-mediated responses in guinea-pig airways
55. 4, and substance P from guinea pig lungs
56. 4 in normal and in asthmatic subjects
57. The role of leukotrienes in inflammation
58. Cytokines in asthma
59. SB 240563: A humanized anti-IL-5 monoclonal antibody; initial single dose safety and activity in patients with asthma
60. Inhaled glucocorticoids for asthma
61. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma
62. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial
63. Effect of corticosteroids on airway hyperresponsiveness
64. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma
65. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids
66. Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids
67. Changes in bronchial inflammation of steroid (GCs) dependent asthmatics
68. 4 by purified human neutrophils
69. Glucocorticoid treatment inhibits apoptosis in human neutrophils: Separation of survival and activation outcomes
70. Prednisone-dependent asthma: Inflammatory indices in induced sputum
71. Effect of glucocorticoids on collagen accumulation in pulmonary vascular remodeling in the rat
72. Dexamethasone-induced increase in platelet-derived growth factor (B) mRNA in human alveolar macrophages and myelomonocytic HL60 macrophage-like cells
73. Evaluation of the anti-inflammatory and phospholipase-inhibitory activity of calpactin II/lipocortin I
74. Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP)
75. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells
76. Granulocyte/macrophage colony-stimulating factor stimulates the expression of the 5-lipoxygenase-activating protein (FLAP) in human neutrophils
77. Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells
78. Selective inhibition of arachidonic acid metabolite release from human lung tissue by anti-inflammatory steroids
79. Arachidonic acid metabolism in normal human alveolar macrophages: Stimulus specificity for mediator release and phospholipid metabolism, and pharmacologic modulation in vitro and in vivo
80. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans
81. Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids
82. 4 biosynthesis in neutrophils from patients with rheumatoid arthritis after a single glucocorticoid dose
83. Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants: Modulation by dexamethasone
84. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
85. 4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy
86. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air
87. Cysteinyl leukotrienes mediate histamine hypersensitivity ex vivo by increasing histamine receptor numbers
88. Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids
89. 1 drop after bronchial challenge in mild asthma
90. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects
91. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: Bronchoalveolar lavage fluid findings after segmental antigen challenge
92. Zafirlukast and low dose beclomethasone protect against early (EAR) and late asthmatic responses (LAR) and allergen induced eosinophilia in mild atopic asthma
93. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
94. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma
95. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma
96. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism
97. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics
98. Leukotriene synthesis inhibition can interrupt antigen-induced sensitisation
99. 4 induced airway inflammation in asthma
100. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial; Montelukast Clinical Research Study Group
101. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial; Montelukast/Beclomethasone Study Group
102. Potential anti-inflammatory effects of montelukast on airways of asthmatics
103. Effect of leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma
104. 4 receptor antagonist, in subjects with bronchial asthma; ACCOLATE Asthma Trialists Group
105. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study; The Zafirlukast Trialists Group
106. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma; Montelukast Asthma Study Group
107. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial; Pediatric Montelukast Study Group
108. Worldwide clinical experience with the first marketed leukotriene receptor antagonist
109. Pranlukast, a novel leukotriene receptor antagonist: Results of the first European, placebo controlled, multicenter clinical study in asthma
110. Improved asthma control > 6 weeks with zafirlukast in patients on high dose inhaled corticosteroids
111. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid: The Tokyo Joshi-Idai Asthma Research Group
112. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma
113. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: A randomized controlled trial; Zileuton Clinical Trial Group
114. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial; Zileuton Study Group
115. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma
116. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma
117. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics
118. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma
119. Is there a unifying hypothesis for exercise-induced asthma?
120. 4 after exercise challenge in children with asthma
121. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist
122. 4-receptor antagonist
123. 4 receptor antagonist
124. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
125. 4-receptor antagonist cinalukast
126. Inhibition of exercise-induced bronchospasm by zileuton: A 5-lipoxygenase inhibitor
127. Oral montelukast compared with inhaled salmeterol to prevent exercise bronchoconstriction: A randomised, double blind trial
128. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction
129. Montelukast for the treatment of exercise-induced asthma in children: Mid-term study
130. The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: The possible role of leukotrienes in exercise-induced refractoriness
131. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin
132. Inhaled corticosteroids versus anti-leukotrienes: A literature review on the clinical effects
133. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial; Montelukast/Beclomethasone Study Group
134. The early onset of action of zafirlukast in patients with asthma